A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
University of Washington
Massachusetts General Hospital
Constellation Pharmaceuticals
Ohio State University Comprehensive Cancer Center
RWTH Aachen University
AbbVie
Incyte Corporation
Novartis
Children's Oncology Group